Bisindolylmaleimide XI hydrochloride (Ro 32-0432) is an orally active pan-PKC inhibitor that inhibits PKCα, PKCβI, PKCβII, and PKCγ (IC50 = 9/28/31/37/108 nM).

PKCβI:28 nM, PKCε:108 nM, PKCγ:37 nM, PKCβII:31 nM, PKCα:9 nM

Bisindolylmaleimide XI hydrochloride (Ro 32-0432) significantly inhibits IL-2 secretion, IL-2 receptor expression, and proliferative capacity in Homo sapiens peripheral T cells. These T cells were activated by phorbol ester combined with phytohemagglutinin or anti-CD3 antibody stimulation. However, this compound shows no significant inhibitory effect on IL-2-induced proliferation in T cells that have already been activated and express IL-2 receptors. For the influenza peptide antigen HA 307-319-specific Homo sapiens T cell clone (HA27), the proliferative response occurring after co-culture with antigen-pulsed autologous antigen-presenting cells can also be effectively suppressed by Bisindolylmaleimide XI hydrochloride [2].
Bisindolylmaleimide XI hydrochloride (1 μM) intervention in retinal progenitor cells (RPCs) reduces the apoptosis ratio by 21% through inhibition of PKC activity [3].

Oral administration of Bisindolylmaleimide XI hydrochloride significantly inhibits phorbol ester-induced subsequent edema reactions in rats.
Bisindolylmaleimide XI hydrochloride can suppress various T cell-mediated physiological immune responses, with typical examples including host rejection reaction against grafts and secondary paw swelling symptoms observed in adjuvant-induced arthritis models [2].